Nanomechanical phenotypes in cMyBP-C mutants that cause hypertrophic cardiomyopathy
C. Suay-Corredera, M. R. Pricolo, D. Velazquez-Carreras, C. Pimenta-Lopes, D. Sanchez-Ortiz, I. Urrutia-Irazabal, S. Vilches, F. Dominguez, G. Frisso, L. Monserrat, P. Garcia-Pavia, E. Herrero-Galan, J. Alegre-Cebollada
Abstract
Hypertrophic cardiomyopathy (HCM) is a disease of the myocardium caused by mutations in sarcomeric proteins with mechanical roles, such as the molecular motor myosin. Around half of the HCM-causing genetic variants target contraction modulator cardiac myosin-binding protein C (cMyBP-C), although the underlying pathogenic mechanisms remain unclear since many of these mutations cause no alterations in protein structure and stability. As an alternative pathomechanism, here we have examined whether pathogenic mutations perturb the nanomechanics of cMyBP-C, which would compromise its modulatory mechanical tethers across sliding actomyosin filaments. Using single-molecule atomic force spectroscopy, we have quantified mechanical folding and unfolding transitions in cMyBP-C mutant domains. Our results show that domains containing mutation R495W are mechanically weaker than wild-type at forces below 40 pN, and that R502Q mutant domains fold faster than wild-type. None of these alterations are found in control, non-pathogenic variants, suggesting that nanomechanical phenotypes induced by pathogenic cMyBP-C mutations contribute to HCM development. We propose that mutation-induced nanomechanical alterations may be common in mechanical proteins involved in human pathologies.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The molecular basis of hypercontractility caused by the hypertrophic cardiomyopathy mutations R403Q and R663H
S. S. Sarkar, D. V. Trivedi, … J. A. Spudich·bioRxiv·Feb 7, 2019
- Mechanical dysfunction induced by a hypertrophic cardiomyopathy mutation is the primary driver of cellular adaptation
S. R. Clippinger, P. E. Cloonan, … M. J. Greenberg·bioRxiv·May 4, 2020
- Mutations in the catalytic domain of human β-cardiac myosin that cause early onset hypertrophic cardiomyopathy significantly increase the fundamental parameters that determine ensemble force and velocity
Arjun S Adhikari, Kristina B Kooiker, … Kathleen M Ruppel·bioRxiv·Aug 9, 2016
- Hypertrophic cardiomyopathy disease results from disparate impairments of cardiac myosin function and auto-inhibition
J. Robert-Paganin, D. Auguin, A. Houdusse·bioRxiv·May 17, 2018
- Beyond the myosin mesa: a potential unifying hypothesis on the underlying molecular basis of hyper-contractility caused by a majority of hypertrophic cardiomyopathy mutations
Suman Nag, Darshan V Trivedi, … James A Spudich·bioRxiv·Jul 24, 2016
- Hypertrophic cardiomyopathy mutations at the folded-back sequestered β-cardiac myosin S1-S2 and S1-S1 interfaces release sequestered heads and increase myosin enzymatic activity
A. S. Adhikari, D. V. Trivedi, … K. M. Ruppel·bioRxiv·Jan 31, 2019